Acelrx Pharmaceuticals Inc (ACRX) Files Form 4 Insider Buying : Mark G Edwards Buys 15,000 Shares

Acelrx Pharmaceuticals Inc (ACRX): Mark G Edwards , director of Acelrx Pharmaceuticals Inc purchased 15,000 shares on May 10, 2016. The Insider buying transaction was reported by the company on May 12, 2016 to the Securities and Exchange Commission. The shares were purchased at $3.15 per share for a total value of $47,250.00 , the company said in a SEC Form 4 Filing.

Other Insider transactions have been reported by the company according to SEC Form 4, on May 20, 2015, Howard B Rosen (CEO) purchased 35,400 shares at $0.00 per share price.On May 7, 2015, Mark G Edwards (director) purchased 40,000 shares at $3.13 per share price.Also, On Apr 23, 2015, Richard Afable (director) purchased 1,000 shares at $10.30 per share price.

Shares of AcelRx Pharmaceuticals Inc (ACRX) ended Tuesday, May 10, 2016 session in red amid volatile trading. The shares closed down -0.07 points or -2.15% at $3.18 with 2,14,077 shares getting traded. Post opening the session at $3.32, the shares hit an intraday low of $3.105 and an intraday high of $3.32 and the price vacillated in this range throughout the day. The company has a market cap of $144 M and the number of outstanding shares has been calculated to be 4,53,12,242 shares. The 52-week high of AcelRx Pharmaceuticals Inc is $5.88 and the 52-week low is $2.59.

AcelRx Pharmaceuticals Inc Money Flow Index Chart

AcelRx Pharmaceuticals Inc. is a development-stage specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of acute pain. The Company’s lead product candidate Zalviso is intended for the management of moderate-to-severe acute pain in hospitalized adult patients. Zalviso consists of sufentanil sublingual tablets delivered by the Zalviso System. The Company has three additional product candidates in clinical development: the Sufentanil Sublingual Tablet BTP Management System (ARX-02) a pain management system for the treatment of cancer patients who suffer from Breakthrough Pain (BTP); the Sufentanil/Triazolam Sublingual Tablet (ARX-03) is a single fixed-dose combination drug product designed to provide mild sedation anxiety reduction and pain relief and Sufentanil Sublingual Single-Dose Acute Pain Tablet (ARX-04) for the treatment of moderate-to-severe acute pain.

Leave a Reply

AcelRx Pharmaceuticals Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on AcelRx Pharmaceuticals Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.